A Practical Adjunct for Resolving Valve Sizing Ambiguity in Bicuspid Aortic Valves During Balloon-Expandable TAVR Authors: Alvin HY Ko, Angus SF Chui Published: 2026 ABSTRACT Corresponding AuthorKey words: aortic valve, bicuspid aortic valve, valve replacement, vascular disease Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic valve (BAV) anatomy continues to present unique challenges in device selection. The trade-off among the risks of aortic rupture, residual paravalvular leak (PVL), and inadequate valve expansion is amplified in BAV with its more complex anatomy, including eccentric aortic valve dimensions, higher calcium burden, a heavily calcified raphe, or associated aortopathy.1 In such cases, standard multidetector computed tomography (MDCT)–based annular sizing alone may not fully resolve the problem of choosing an appropriately sized transcatheter heart valve (THV), often leaving operators to choose between 2 consecutive valve sizes (eg, size X vs size X + 1) in cases of borderline anatomy. The case series by Satomi et al2 in this issue of JACC: Case Reports offers a straightforward, intraprocedural strategy using balloon predilatation with contrast injection to guide this decision during TAVR with balloon expandable valve (BEV). The BAV Sizing Dilemma Comprehensive multilevel MDCT assessment—incorporating annular, supra-annular and sinotubular junction measurements; Sievers morphological classification; and detailed quantitative evaluation of leaflet, raphe, and left ventricular outflow tract (LVOT) calcification—remains the foundational standard for THV sizing in BAV TAVR.3,4 These imaging elements provide essential 3-dimensional anatomic insights and are indispensable for identifying high-risk features such as tapered configuration and asymmetric calcium distribution. Nevertheless, even with refined multilevel and morphological protocols, borderline cases persist in which the optimal size between consecutive THVs remains uncertain. The authors describe 2 patients with severe aortic stenosis and type 1 BAV of tapered morphology and heavy calcification. In both patients, MDCT measurements indicated borderline sizing between consecutive BEV sizes. Predilatation was performed with a semicompliant balloon 1 size smaller than the smaller candidate valve (22-mm for the 23/26-mm debate in case 1; 18-mm for the 20/23-mm debate in case 2) under angiographic guidance with contrast injection. The key observation was residual balloon indentation without (or with minimal) contrast backflow into the left ventricle. In case 1, although the authors noted the presence of residual balloon indentation without contrast backflow during predilatation, TAVR was performed using the larger 26-mm BEV with underfilling; postprocedural imaging confirmed inadequate midvalve expansion (21.3-mm diameter at midportion) despite postdilatation. In case 2, with similar observation noted during predilatation, the implanters used a smaller 20-mm BEV, resulting in excellent expansion and complete apposition without rupture or PVL. These findings support a practical algorithm: When MDCT leaves residual uncertainty between size X and size X + 1, predilatation with an appropriately undersized balloon should be performed; persistent indentation without significant left ventricular contrast regurgitation favors selection of the smaller valve (size X) to balance the 3-way risk. This balloon-sizing strategy with contrast injection is noteworthy for its simplicity, immediacy, and low additional procedural burden. It provides real-time direct feedback on annular and supra-annular compliance and sealing behavior that static MDCT measurements cannot capture. Intraprocedural balloon sizing also serves as a simulated deployment, offering incremental information on the impact of a heavily calcified raphe or asymmetric calcification—situations in which the symmetrically deployed valve is often displaced toward the less calcified (weaker) side. Furthermore, it can help predict risks of coronary obstruction, PVL, asymmetric valve expansion, and annular rupture.5 Balloon predilatation therefore functions not as a replacement for, but as a valuable adjunct to, rigorous multilevel MDCT assessment when imaging dilemmas remain. The article's timing is particularly relevant amid evolving imaging-based sizing strategies for BAV. Recent work by Yao et al6 demonstrated that a standardized multiplanar supra-annular measurement protocol frequently leads to intentional downsizing in BAV compared with traditional annulus-based sizing, with favorable procedural outcomes and reduced need for valve-in-valve intervention. An accompanying editorial by Jilaihawi, Patel, and Makkar7 underscores the need for detailed, level-specific assessment of heterogeneous BAV anatomy. Similarly, the ABC bicuspid sizing protocol for the SAPIEN 3 BEV integrates annular, LVOT, and intercommissural distance measurements to refine selection.8 These approaches highlight the primacy of high-quality, multilevel MDCT with comprehensive morphological and calcium evaluation. When ambiguity in device sizing persists despite such advanced imaging, the balloon-sizing strategy described here complements these anatomic refinements by adding an intraprocedural functional test, serving as a useful complementary strategy. The article also underscores the concrete drawbacks of oversizing in heavily calcified, tapered type 1 BAV. In case 1, selection of the larger valve—guided primarily by annular area despite the tapered configuration—resulted in underexpansion of the midportion of the prosthesis. Such underexpansion is associated with increased risks of structural valve deterioration, prosthetic valve thrombosis, and suboptimal long-term hemodynamics.9,10 Oversizing may additionally heighten the risk of aortic root injury during deployment or postdilatation, particularly when calcification extends into the LVOT.1,11 The balloon-predilatation approach helps operators avoid these downstream consequences while still mitigating PVL. Looking Forward Important limitations must be acknowledged before widely adopting this approach. This is a small case series (n = 2), and the proposed algorithm should be considered hypothesis generating. The observations require validation in larger cohorts with longer term follow-up to assess durability, PVL rates, and hemodynamic performance. The approach is described specifically for type 1 tapered BAV treated with BEVs; generalizability to other BAV subtypes, self-expanding valves, or less calcified anatomies remains uncertain. Balloon predilatation itself carries a small but real risk of acute aortic regurgitation or hemodynamic instability, although the authors appropriately prepared for rapid valve deployment. Operator experience and precise balloon selection remain critical. In summary, Satomi et al2 reinforce the essential role of high-quality, multilevel MDCT assessment while demonstrating how undersized balloon predilatation with contrast can serve as a pragmatic adjunct when imaging leaves a sizing dilemma. By integrating balloon indentation and contrast dynamics with contemporary CT protocols, this strategy equips structural heart teams to navigate the persistent challenge of optimal BEV sizing in complex BAV anatomy. As TAVR expands to younger and lower-risk populations, including those with BAV, such integrated anatomic and physiologic tools will be essential to maintain safety, procedural success, and long-term valve durability. Future prospective studies incorporating this technique alongside advanced imaging could further define its role in standardized BAV TAVR workflows. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References